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ABSTRACT Many pathogens evolve extensive genetic variation in virulence proteins
as a strategy to evade host immunity. This poses a signiﬁcant challenge for the host
to develop broadly neutralizing antibodies. In Plasmodium falciparum, we show that
a mechanism to circumvent this challenge is to elicit antibodies to cryptic epitopes
that are not under immune pressure. We previously discovered that antibodies to
the Plasmodium vivax invasion protein, PvDBP, cross-react with P. falciparum
VAR2CSA, a distantly related virulence factor that mediates placental malaria. Here,
we describe the molecular mechanism underlying this cross-species immunity. We
identiﬁed an epitope in subdomain 1 (SD1) within the Duffy binding-like (DBL) do-
main of PvDBP that gives rise to cross-reactive antibodies to VAR2CSA and show
that human antibodies afﬁnity puriﬁed against a synthetic SD1 peptide block para-
site adhesion to chondroitin sulfate A (CSA) in vitro. The epitope in SD1 is subdomi-
nant and highly conserved in PvDBP, and in turn, SD1 antibodies target cryptic
epitopes in P. falciparum VAR2CSA. The epitopes in VAR2CSA recognized by vivax-
derived SD1 antibodies (of human and mouse origin) are distinct from those recog-
nized by VAR2CSA immune serum. We mapped two peptides in the DBL5 domain
of VAR2CSA that are recognized by SD1 antibodies. Both peptides map to regions
outside the immunodominant sites, and antibodies to these peptides are not elicited
following immunization with VAR2CSA or natural infection with P. falciparum in
pregnancy, consistent with the cryptic nature of these target epitopes.
IMPORTANCE In this work, we describe a molecular mechanism of heterologous im-
munity between two distant species of Plasmodium. Our results suggest a mecha-
nism that subverts the classic parasite strategy of presenting highly polymorphic
epitopes in surface antigens to evade immunity to that parasite. This alternative im-
mune pathway can be exploited to protect pregnant women from falciparum pla-
cental malaria by designing vaccines to cryptic epitopes that elicit broadly inhibitory
antibodies against variant parasite strains.
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Heterologous immunity can develop when prior exposure to one pathogen mod-ulates the host immune response to pathogens of genetically diverse species. This
form of immunity can be induced by vaccination or arise from natural infection and
lead to protective or deleterious outcomes following infection with a different organ-
ism. One of the classic examples of heterologous protection is the success of the
cowpox vaccine in eradicating human smallpox. More recently, vaccination with the
meningococcal B vaccine correlated with reduced incidence of gonorrhea (1, 2), and
natural exposure to the nontuberculous mycobacteria in the environment can induce
heterologous immunity to Mycobacterium tuberculosis (3). This phenomenon can also
be modeled in mice, where immunization or infection with one virus protects against
heterologous viral challenge (4). For example, infection with inﬂuenza A virus can
protect against challenge with respiratory syncytial virus (RSV) and vaccinia virus (5, 6)
and immunization with adenovirus can protect against hepatitis C virus (7). Similarly,
infection with Japanese encephalitis virus in mice can prime the immune response and
promote rapid viral clearance following heterologous challenge with Zika virus (8).
Despite the evidence that cross-species immunity can be highly protective, it
remains controversial whether this form of immunity plays a role in protection from
malaria. Malaria is a parasitic disease caused by ﬁve species of Plasmodium with
overlapping endemicity in many geographic areas. Population-based data from several
regions where multiple species of Plasmodium coexist, such as South Asia, Southeast
Asia and parts of Oceania, are consistent with heterologous immunity against Plasmo-
dium falciparum following prior infection with Plasmodium vivax (9–13). However, the
mechanism of heterologous immunity to malaria is not deﬁned. In humans, T cells
induced by vaccination with P. falciparum respond in vitro to Plasmodium knowlesi-
infected red blood cells, suggesting a role for the cellular arm of the immune system
(14). In other studies, there is clearly heterologous cross-reactivity between antibodies
as sera from patients infected with P. vivax cross-reacted with antigens from P.
falciparum (15–19). These antibodies may cross-react with orthologous proteins in-
volved in the same biological pathways in each species, such as PfMSP5/PvMSP5 (20),
PfCLAG9/PvCLAG9 (21), PfAMA-1/PvAMA-1 (22), PfCSP/PvCSP and PfMSP-1/PvMSP-1
(23), and between Pfs48/45 and Pvs48/45 (24). However, functional activity of these
cross-reactive antibodies was not reported.
We recently identiﬁed cross-species immune recognition between two homologous
parasite proteins that are implicated in distinct biological pathways—P. vivax DBP
(PvDBP) and P. falciparum VAR2CSA (25). PvDBP is a protein expressed on the surface
of merozoites that mediates invasion into red blood cells by binding to the Duffy
antigen receptor for chemokines (DARC) (26). VAR2CSA, on the other hand, is expressed
by mature P. falciparum trophozoites and mediates sequestration of infected red blood
cells (iRBCs) in the placenta (27–30). Sequestration is a common immune evasion
mechanism thought to prevent destruction of iRBCs in the spleen and involves the
interaction between certain antigenic variants of the P. falciparum erythrocyte mem-
brane protein 1 (PfEMP1) family expressed on the surface of iRBCs with speciﬁc host
receptors in different tissues (31). In pregnancy, parasites express the PfEMP1 variant
VAR2CSA, which binds to chondroitin sulfate A (CSA) in the placenta. Placental seques-
tration is an important feature of malaria in pregnancy that can lead to poor outcomes
for mother and baby, including stillbirth, preterm birth, low birthweight, and maternal
anemia and death (32–34).
Most studies that evaluated the acquisition of VAR2CSA antibodies have focused on
women in sub-Saharan Africa, where P. falciparum is the dominant species (35). These
studies showed parity-dependent anti-VAR2CSA antibody acquisition, which occurred
following multiple malaria infections in pregnancy (29). We discovered an alternate
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route of anti-VAR2CSA antibody acquisition outside pregnancy in areas where P. vivax
and P. falciparum cocirculate (25). We showed that cross-reactivity is mediated by Duffy
binding-like (DBL) domains, which are structurally conserved domains present in many
Plasmodium proteins, including VAR2CSA, which has 6 DBL domains (30), and PvDBP,
which has one (36). Antibodies against the DBL domain in region II of PvDBP (DBPII)
from nonpregnant populations exposed to P. vivax recognized VAR2CSA by enzyme-
linked immunosorbent assay (ELISA). Moreover, a mouse monoclonal antibody (MAb)
against DBPII recognized VAR2CSA and blocked parasite adhesion to CSA in vitro.
Here, we probed the underlying mechanism of heterologous immunity to VAR2CSA.
We identiﬁed a subdominant epitope in DBPII that mediates cross-reactivity to
VAR2CSA and show that human antibodies puriﬁed against this epitope block iRBC
adherence to CSA. Furthermore, both the human epitope-speciﬁc antibodies and the
mouse MAb recognize overlapping, cryptic epitopes in VAR2CSA.
RESULTS
SD1ss contains the epitope in DBPII that is recognized by 3D10 and mediates
cross-reactivity to VAR2CSA. We showed previously that the 3D10 MAb against DBPII
cross-reacted with VAR2CSA and blocked parasite adhesion to CSA in vitro (25). The
epitope recognized by 3D10 is predicted to localize to subdomain 1 (SD1) of DBPII
based on mutational analysis of this domain and peptide library screening with the
MAb (37, 38). We designed a synthetic peptide, SD1ss, which spans the 39-amino-acid
SD1 sequence and mutated the two outer cysteine residues to serines to ensure
formation of a single disulﬁde bond (Fig. 1A). We conﬁrmed 3D10 recognition of SD1ss
by ELISA and found that 3D10 had the same endpoint titer against DBPII and SD1ss
(0.17 ng/ml) (Fig. 1B).
We then tested the ability of the SD1ss peptide to block 3D10 recognition of DBPII
using a competition ELISA. In this assay, 3D10 was incubated with increasing concen-
trations of SD1ss and then added to wells coated with DBPII (Fig. 1C). As a negative
control, 3D10 was incubated with C29-K40 (at 1.0 g/ml), a short peptide within SD1
that is not recognized by 3D10 (see Fig. S1 in the supplemental material). SD1ss
blocked recognition of DBPII by 3D10 at a concentration of 1.0 g/ml (Fig. 1C),
conﬁrming that this peptide contains the epitope that mediates recognition of DBPII.
Next, we performed a competition ELISA with full-length recombinant VAR2CSA as the
capture antigen. When 3D10 was incubated with SD1ss (at 1.0 g/ml), but not C29-K40,
recognition of VAR2CSA was blocked (Fig. 1D), showing that SD1ss contains an epitope
that mediates cross-reactivity to VAR2CSA.
SD1ss is a subdominant epitope in PvDBP. To test whether SD1ss is a dominant
epitope in PvDBP, we generated and tested polyclonal sera to DBPII in BALB/c mice
using the same strain of mice and the same allele of DBPII (Sal 1) that gave rise to the
3D10 MAb. Total IgG from mice immunized with Sal 1 DBPII recombinant protein did
not recognize SD1ss by ELISA, despite high antibody titers to DBPII (Fig. 2A). These
antibodies also failed to recognize full-length VAR2CSA. These data demonstrate that
SD1 is subdominant in this strain of mouse and are consistent with the observation that
of 7 MAbs generated to DBPII, only 3D10 recognizes the SD1 region (37, 38).
To investigate this in a human population, we tested sera from individuals infected
during a P. vivax outbreak in Brazil that occurred in an otherwise malaria-free region
(39). Sera from individuals who experienced P. vivax relapses developed a range of
DBPII antibodies (Fig. 2B) but failed to recognize SD1ss (Fig. 2C). These human sera did
not recognize VAR2CSA (Fig. 2D), consistent with the mouse data that polyclonal
antibodies against DBPII that lack speciﬁcity for SD1ss do not cross-react with VAR2CSA.
It is possible that these sera failed to recognize SD1ss due to polymorphisms between
the peptide sequence and the SD1 sequence in the outbreak clone. However, when we
sequenced the SD1 region from P. vivax genomic DNA (gDNA) isolated from a patient
during the outbreak, the sequence was 100% identical to SD1 in Sal 1, the strain used
to design the SD1ss peptide. Furthermore, a BLASTp search of the SD1 amino acid
sequence showed that it was 100% identical to the top 100 P. vivax SD1 sequences from
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global isolates, suggesting that this region of DBPII is highly conserved and not under
immune selection.
We showed previously that P. vivax-exposed Brazilian men and children residing in
Rio Pardo, an area of malaria endemicity in the Amazon, had antibodies against
VAR2CSA (25). Based on this ﬁnding, and the data above, we postulated that the SD1
epitope in PvDBP is poorly immunogenic. To address this, we tested sera from Brazilian
men and children with lifelong exposure to P. vivax for antibodies to SD1ss and DBPII.
We observed that 78% had antibodies to DBPII whereas only 39% had antibodies to
SD1ss. The antibody levels were correlated (rs  0.7014, P 0.0001) (Fig. 3A), but half
of those who had DBPII antibodies did not have SD1ss antibodies. These ﬁndings are
consistent with the mouse and outbreak data showing that exposure to DBPII does not
always elicit an antibody response against SD1ss and conﬁrm that this epitope in
PvDBP is subdominant in human populations.
We then correlated the seroreactivity to DBPII and SD1ss with VAR2CSA reactivity
and found that VAR2CSA antibody levels were correlated with both DBPII (rs  0.5443,
P 0.0002) and SD1ss (rs  0.6192, P 0.0001) (Fig. 3B and C). To assess the speciﬁcity
of these interactions, the sera were tested against another P. vivax merozoite protein,
EBP2. This protein is a homologue of DBPII, but the SD1-like region is signiﬁcantly
different from DBPII, and the 3D10 MAb does not recognize this protein (40). Antibody
FIG 1 SD1ss contains an epitope in DBPII that is recognized by 3D10 and mediates cross-reactivity to VAR2CSA.
(A) DBPII crystal structure (PDB ID 4NUU) showing the SD1 region in blue. The disulﬁde bond in SD1ss is
represented by space-ﬁlling spheres. (B) Titration of 3D10 against recombinant DBPII and synthetic SD1ss. (C and
D) 3D10 was incubated alone (black bar) or with SD1ss (teal bars) or the shorter peptide C29-K40 (purple bars) before
being added to wells coated with DBPII (C) or VAR2CSA (D). Data are mean  standard deviation (SD).
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levels against EBP2 did not correlate with VAR2CSA reactivity in this population (rs 
0.2789, P 0.0774) (Fig. 3D).
We observed similar correlations of antibody levels in sera from men and children
living in an area of Colombia where both P. vivax and P. falciparum are endemic (Fig. 4).
These subjects were not selected based on past or current malaria infection and
represent a more heterogeneous population in terms of malaria exposure. DBPII
recognition was signiﬁcantly correlated with SD1ss antibody levels (rs  0.5337,
P 0.0001), and VAR2CSA antibodies correlated with both DBPII (rs  0.4046,
P 0.0001) and SD1ss (rs  0.2353, P 0.0028) antibody levels (Fig. 4A to C). Again,
there was no correlation between EPB2 and VAR2CSA antibody levels (rs  0.0472,
P 0.5372) (Fig. 4D).
SD1ss afﬁnity-puriﬁed human antibodies block parasite adhesion to CSA in
vitro. Our data thus far suggest that antibodies to the epitope in PvDBP SD1 cross-react
with VAR2CSA. To test this directly, we afﬁnity puriﬁed antibodies that recognize SD1ss
from a pool of sera from nonpregnant populations in Colombia (men and children)
exposed to P. vivax and P. falciparum. Similarly, we afﬁnity puriﬁed antibodies that
recognize the entire DBPII recombinant protein. As expected from our immunogenicity
data above, the DBPII afﬁnity-puriﬁed antibodies recognized SD1ss very weakly
(Fig. 5A). They did recognize EBP2, presumably through shared epitopes in the DBL
domain. In contrast, the SD1ss afﬁnity-puriﬁed antibodies recognized DBPII but not
EBP2, consistent with poor sequence conservation of the SD1-like region in EBP2.
FIG 2 The SD1 domain of DBPII is subdominant. (A) Total IgG pooled from 15 mice immunized with the
Sal 1 allele of DBPII was tested against DBPII, SD1ss, and VAR2CSA by ELISA. IgG was tested at a
concentration of 0.1 g/ml against DBPII and 5.0 g/ml against SD1ss and VAR2CSA. (B to D) Sera from
individuals infected during an outbreak of P. vivax in a malaria-free region of Brazil were tested by ELISA
against DBPII (B), SD1ss (C), and VAR2CSA (D). The cutoff was deﬁned as 2 standard deviations above the
mean OD of unexposed Brazilians tested against the same antigens. A pool of sera from individuals living
in an area of malaria endemicity in Brazil was included as a positive control. Data are mean  SD.
Heterologous Immunity to DBL Proteins in Plasmodium ®
September/October 2019 Volume 10 Issue 5 e02343-19 mbio.asm.org 5
 o
n
 O
ctober 21, 2019 at Copenhagen University Library
http://m
bio.asm
.org/
D
ow
nloaded from
 
Neither of the puriﬁed antibodies recognized PfMSP1, an unrelated P. falciparum
merozoite antigen. Both afﬁnity-puriﬁed antibodies cross-reacted with VAR2CSA, and
the reactivity of the SD1ss afﬁnity-puriﬁed antibodies was higher than the DBPII
afﬁnity-puriﬁed antibodies (Fig. 5B).
A critical question is whether the afﬁnity-puriﬁed antibodies could protect against
placental malaria. This can be measured in vitro using an inhibition-of-binding assay
(IBA) to test if antibodies block parasite adhesion to CSA. Mature VAR2CSA-expressing
P. falciparum CS2 trophozoites were incubated with the afﬁnity-puriﬁed IgG and then
added to immobilized CSA. The number of parasites bound per spot of CSA was
quantiﬁed and compared to binding in the presence of IgG from a pool of unexposed
Colombians as the negative control. We found that the DBPII afﬁnity-puriﬁed IgG
reduced parasite binding to CSA, but the effect was not signiﬁcant (Fig. 5C). However,
SD1ss afﬁnity-puriﬁed IgG blocked parasite adhesion to CSA, and the effect was
signiﬁcant in three of four experiments (Fig. 5D). The inhibition in these three experi-
ments ranged from 32 to 45%.
Antibodies to SD1 in PvDBP target cryptic epitopes in VAR2CSA. To better
understand this mechanism of cross-species immunity, we investigated whether anti-
bodies that developed following exposure to P. falciparum VAR2CSA would reciprocally
recognize the epitope in PvDBP SD1. We ﬁrst tested plasma collected from multigravid
women from Uganda who were naturally exposed to VAR2CSA during pregnancy
FIG 3 SD1ss antibodies correlate with VAR2CSA antibodies in sera from Brazilian men and children with exposure
to P. vivax only. Individual sera from men and children from Rio Pardo, Brazil, were selected based on past exposure
to P. vivax only. Sera were tested by ELISA for reactivity to DBPII, SD1ss, VAR2CSA, and EBP2. Antibody levels (ODs)
were converted to arbitrary units (AU) based on the positive control included on every plate. Serum reactivity was
correlated using Spearman rank correlation. rs, Spearman rank coefﬁcient.
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(Fig. 6A). Despite high levels of VAR2CSA-speciﬁc antibodies, there was no recognition
of SD1ss. Pooled sera from Ugandan children were included as a negative control. Sera
from Colombian men and children that recognized both VAR2CSA and SD1ss were
included as a positive control. To investigate this further, we tested serum from a rabbit
that was immunized with recombinant VAR2CSA. Similarly to the human sera, the
rabbit serum did not recognize SD1ss (Fig. 6B).
These data imply that cross-reactive antibodies (elicited against SD1) and VAR2CSA-
induced antibodies recognize distinct epitopes in VAR2CSA. To test this further, we
performed an antibody-based competition ELISA using the 3D10 MAb and VAR2CSA
antibodies induced through immunization (in rabbits). Initially, rabbit anti-VAR2CSA
serum or normal rabbit serum (NRS) (as a control) was added to wells coated with
VAR2CSA. Then, the detecting antibody (anti-DBL5 mouse serum, 3D10 MAb, or
human SD1ss afﬁnity-puriﬁed antibodies) was added. The rabbit anti-VAR2CSA anti-
body strongly blocked recognition by the anti-DBL5 serum, compared to the NRS
(Fig. 6C), consistent with recognition of shared immunodominant epitopes by these
sera. However, VAR2CSA rabbit antiserum could not block recognition of VAR2CSA by
3D10 (Fig. 6D), demonstrating that the epitope on VAR2CSA recognized by 3D10 was
not recognized by the polyclonal rabbit antiserum. Similarly, the rabbit polyclonal
antiserum could not block recognition of VAR2CSA by human SD1ss afﬁnity-puriﬁed
antibodies (Fig. 6E), demonstrating that, like 3D10, the epitope(s) on VAR2CSA recog-
FIG 4 SD1ss antibodies correlate with VAR2CSA antibodies in sera from Colombian men and children. Sera from men
and children living in an area of malaria endemicity in Colombia were tested for reactivity to DBPII, SD1ss, VAR2CSA, and
EBP2 by ELISA. Antibody levels (ODs) were converted to arbitrary units (AU) based on the positive control included on
every plate. Serum reactivity was correlated using Spearman rank correlation. rs, Spearman rank coefﬁcient.
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nized by human antibodies that arose as a result of P. vivax exposure is distinct from
those that are immunogenic in VAR2CSA. Thus, the epitopes on VAR2CSA recognized
by 3D10 and by humans following P. vivax exposure are classical cryptic epitopes. To
ask whether the human and mouse cryptic epitopes are the same, we tested whether
SD1ss afﬁnity-puriﬁed human antibodies could block recognition of 3D10 (Fig. 6F). We
demonstrated partial but signiﬁcant blocking, suggesting that these epitopes overlap
but may not be identical.
Cryptic epitopes in the DBL5 domain of VAR2CSA. VAR2CSA is a large multi-
domain protein that could contain many target epitopes for the cross-reactive anti-
bodies derived from SD1. We focused on mapping the epitopes in one domain, DBL5,
as this domain is among the more conserved DBL domains in VAR2CSA and we showed
previously that this domain is strongly recognized by the 3D10 MAb (25). We generated
an array of overlapping peptides that span the DBL5 domain and screened this array
with 3D10 (Fig. 7). Two peptides were strongly recognized (P20 and P23), while two
others (P4 and P15) were weakly recognized. To validate these peptides further, we
performed competition ELISAs and tested whether each peptide could compete out
the recognition of DBL5 by 3D10 (Fig. 8A). Only P20 and P23 signiﬁcantly reduced the
recognition by 3D10. While the effect with each peptide was partial, there was no
synergistic effect of combining the two peptides (Fig. 8A).
FIG 5 SD1ss afﬁnity-puriﬁed antibodies recognize VAR2CSA and block iRBC adhesion to CSA. (A and B) Pooled sera
from Colombian men and children were afﬁnity puriﬁed on DBPII or SD1ss. Total IgG puriﬁed from unexposed
Colombians was used as a negative control. Antibodies were tested against various antigens by ELISA. (C and D)
Afﬁnity-puriﬁed DBPII (100 g/ml) (C) and SD1ss (90 g/ml) (D) antibodies were tested in the inhibition-of-binding
assay using P. falciparum CS2 parasites expressing VAR2CSA. Data are from independent experiments. Data are
mean  SD, and signiﬁcance was determined using Student’s t test comparing unexposed Colombian IgG and
afﬁnity-puriﬁed IgG for each experiment. **, P 0.01; ***, P 0.001; ns, not signiﬁcant.
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We next determined whether the epitopes in P20 and P23 were cryptic in DBL5.
Whereas the pools of sera from Colombian and Brazilian men and children exposed
only to P. vivax strongly recognized these same peptides (Fig. 8B), they were not
recognized by the sera from either Ugandan multigravid women (Fig. 8C) or the rabbit
immunized with VAR2CSA (Fig. 8D).
To visualize the P20 and P23 epitopes within the protein structure of DBL5, we
mapped the two peptide sequences onto a homology model of the DBL5 (3D7)
domain. Both peptides mapped to alpha helices in subdomain 3 (Fig. 8E). These sites
are distinct from the immunodominant epitopes recognized by sera from Tanzanian
multigravid women (Fig. 8F, blue) and a rabbit immunized with VAR2CSA (41) and share
no overlap with the putative CSA binding sequence in this domain (Fig. 8E, yellow) (42).
P20 and P23 share only limited amino acid sequence homology with SD1ss; P20
contains two cysteine residues, while P23 contains one cysteine as well as the motif
FIG 6 Epitopes in VAR2CSA recognized by vivax-derived antibodies are cryptic. (A) Pooled sera from Ugandan children
andmultigravid women were tested by ELISA against VAR2CSA and SD1ss. Sera from Colombianmen and children were
used as a positive control. (B) Anti-VAR2CSA rabbit serum were tested by ELISA against VAR2CSA and SD1ss. (C to F)
Competition ELISAs with VAR2CSA as the capture antigen and either anti-VAR2CSA rabbit serum (C to E) or human SD1ss
afﬁnity-puriﬁed antibodies (F) as the competing antibody. 3D10 (D and F) or human SD1ss afﬁnity-puriﬁed antibodies
(E) were added as the source of detection antibodies. Data are mean  SD, and signiﬁcance was determined using a
one-way ANOVA with multiple-comparison test. *, P0.05; ****, P0.0001; ns, not signiﬁcant; AP, afﬁnity-puriﬁed.
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RKR, which is important for recognition of SD1 by 3D10 (37, 38). We therefore
investigated the possibility that 3D10 recognized a conformational epitope in these
peptides. To test this, we measured 3D10 reactivity to each peptide after treatment
with dithiothreitol (DTT), which would abolish disulﬁde bonding either within or
between peptide molecules. When P20 and P23 were treated with DTT, 3D10 recog-
nition was lost (Fig. S2). Interestingly, 3D10 recognition of SD1ss was also reduced
following treatment of the peptide with DTT, suggesting that the disulﬁde bond is
important for recognition of the homologous epitopes.
DISCUSSION
We discovered a host defense mechanism in Plasmodium in which a subdominant
epitope in the P. vivax antigen PvDBP elicits functional antibodies against cryptic
epitopes in the distantly related P. falciparum homologue VAR2CSA. We mapped
the epitope in PvDBP to SD1 and showed that human antibodies to this epitope
recognized VAR2CSA and blocked parasite adhesion to CSA. Our data suggest that SD1
is subdominant in PvDBP by virtue of its poor immunogenicity in mice vaccinated with
the Sal 1 allele of PvDBP and our ﬁndings that about half of individuals exposed to
PvDBP do not develop SD1 antibodies. However, the levels of SD1 antibodies correlated
with the levels of VAR2CSA reactivity. This is consistent with ﬁndings from another
study where volunteers were deliberately infected with the P. vivax Sal 1 strain and did
not have cross-reactive antibodies to VAR2CSA (43). We expect that the Sal 1 strain of
PvDBP does not readily elicit SD1 antibodies in humans, as we observed in mice. While
the mechanism that gives rise to SD1-speciﬁc antibodies during natural P. vivax
infection is not known, certain alleles of PvDBP may adopt protein structures that
preferentially expose SD1, or perhaps SD1 antibodies arise through afﬁnity maturation
following exposure to multiple, different PvDBP alleles. Alternatively, host genetic
variability in HLA class II genes may also play a role in directing the antibody responses,
as we reported previously for DBPII (44).
Antibodies to SD1 of PvDBP appear to have no protective value against P. vivax
infection. The epitope is weakly immunogenic, and antibodies that do arise, such as
3D10 in mice, do not inhibit binding to DARC or block P. vivax invasion of reticulocytes
(45). Moreover, the amino acid sequence of SD1 is highly conserved, which is consistent
with our interpretation that this subdomain is not under immune pressure. Likewise,
our data strongly suggest that antibodies to SD1 target cryptic epitopes in VAR2CSA.
Immune serum from a rabbit immunized with VAR2CSA failed to compete with the
human SD1ss afﬁnity-puriﬁed antibodies or the mouse 3D10 MAb for recognition sites
on VAR2CSA. Yet, the binding of SD1 antibodies to these cryptic epitopes can block
FIG 7 3D10 recognizes epitopes in DBL5. An array of overlapping peptides that span DBL5 was tested with the
DBPII MAb 3D10 compared with a mouse IgG1 isotype control. P20 and P23 are in bold.
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parasite adhesion to CSA. We do not know whether the epitopes recognized by the
vivax-derived antibodies are within the CSA binding sites of VAR2CSA or if the anti-
bodies block adhesion by steric hindrance. However, the two peptides that we iden-
tiﬁed in the DBL5 array map to sites distal to the predicted CSA binding sequence in
this domain (42). They are also distinct from the immunodominant epitopes that were
recognized by African multigravid women (41). Further work is needed to identify the
target epitopes in other DBL domains of VAR2CSA and how they map to the three-
dimensional structure of the full protein.
FIG 8 Recognition of speciﬁc peptides in the DBL5 domain of VAR2CSA by vivax-derived antibodies. (A)
Competition of 3D10 recognition of DBL5 by individual peptides. 3D10 was incubated with peptides P20, P23, P20
and P23 in combination, P4, and P15 (all at 100 g/ml) and added to a plate coated with DBL5 protein. The OD
of 3D10 preincubated with each peptide was compared to the OD for the antibody alone (no competitor). NC, no
competitor. (B to D) Recognition of P20 and P23 by sera from Colombians and Brazilians exposed only to P. vivax
(B), children and multigravid women from Uganda (C), and a rabbit immunized with full-length VAR2CSA (D) was
tested by ELISA. (E) Homology model of DBL5 depicting P20 (orange), P23 (red), and the putative glycosamino-
glycan binding site (yellow) (42). (F) Homology model of DBL5 depicting the surface-exposed regions recognized
by sera from multigravid African women (blue), some of which overlap (green) the putative glycosaminoglycan
binding site (yellow) (42). Data are mean  SD, and signiﬁcance was determined using a one-way ANOVA with
multiple-comparison test (***, P 0.001; ****, P 0.0001).
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To our knowledge, this is the ﬁrst demonstration of adhesion-blocking antibodies that
target cryptic epitopes in VAR2CSA. Antibodies can access cryptic epitopes through various
mechanisms. Epitopes concealed within the head domain of the inﬂuenza A hemagglutinin
protein are transiently exposed to antibodies during dynamic changes in the conformation
of the trimer complex, through a process described as “breathing” (46–48). Similarly, several
studies on dengue virus and West Nile virus revealed time- and temperature-dependent
exposure of cryptic epitopes, reﬂecting the important role of structural dynamics in epitope
accessibility (49–52). VAR2CSA forms a large globular complex that may undergo similar
protein dynamics, exposing cryptic epitopes within intermediate protein conformations
that arise during transport to the cell surface, posttranslational modiﬁcation/protein mat-
uration, interaction with other knob proteins, or upon binding to CSA. The idea that these
epitopes are exposed in only a subset of protein structures is consistent with our previous
ﬁnding that the 3D10 MAb recognized only a small percentage of iRBCs that expressed
native VAR2CSA on the cell surface (25).
The discovery of cryptic epitopes in VAR2CSA has direct applications for vaccine
development against placental malaria. A signiﬁcant obstacle to current vaccine strategies
is the highly polymorphic nature of var2csa alleles (53), which impedes development of
broadly neutralizing antibodies against diverse parasite strains. In a recent study of 247 P.
falciparum isolates (54), 171 polymorphic loci were identiﬁed in the ID1-DBL2Xb subregion
that is included in two vaccines against pregnancy-associated malaria (55, 56). A different
study identiﬁed 4 major domain clades in this region (57). The effects of these polymor-
phisms are highlighted by several reports that functional antibodies to VAR2CSA in differ-
ent populations of African women are highly strain speciﬁc, reﬂecting seroreactivity to
immunodominant epitopes (58–60). Our ﬁnding that SD1 from P. vivax elicits protective
antibodies against cryptic epitopes in VAR2CSA provides an alternative, yet complemen-
tary, vaccine strategy that could circumvent this immune pressure.
Epitope-speciﬁc vaccines that direct the immune response to cryptic or subdomi-
nant epitopes are emerging as a viable strategy against many pathogens for which
traditional vaccine approaches were unsuccessful (61, 62). These vaccine candidates
include conserved epitopes in otherwise highly mutable viruses, such as HIV (63, 64),
Ebola virus (65, 66), and inﬂuenza virus (46–48, 67, 68), as well as pathogenic bacteria,
such as Streptococcus pyogenes (69), anthrax and Staphylococcus aureus (61). A critical
advantage is that many of these epitopes can induce broadly neutralizing, strain-
transcending immunity by eliciting antibodies that cross-react with related but anti-
genically distinct pathogens (66, 69, 70).
In summary, we show that antibodies to a highly conserved, subdominant epitope
in P. vivax inhibit an unrelated virulence pathway in P. falciparum in vitro. It will be
important in future clinical studies to determine whether these antibodies contribute to
improved birth outcomes from P. falciparum placental malaria and to evaluate whether
SD1 can elicit polyclonal neutralizing antibodies through immunization. While our data
make SD1 an attractive epitope for future vaccine design, they also provide insight into
an unusual mechanism of heterologous immunity to Plasmodium based on shared
epitopes across the DBL protein family.
MATERIALS AND METHODS
Human subjects. Approval for this study was granted by the Health Research Ethics Board of the
University of Alberta in Canada (approval Pro00041720); the Comité de Ética of the Instituto de
Investigaciones Médicas of the Universidad de Antioqua in Colombia (approvals 009-2013, 002-2015, and
009-2016); the Ethics Committee of the Fundação Oswaldo Cruz, the Brazilian Health Ministry, and the
Ethical Committee of Research on Human Beings from the CPqRR/Fundação Oswaldo Cruz (reports
07/2009 and 26/2013; CAEE:50522115.7.0000.5091/05/2016); and the Higher Degrees, Research, and
Ethics Committee in Uganda (HDREC approval 386). Participation in all studies was voluntary, and each
participant provided written consent.
Samples from individuals in Colombia, Brazil, and Uganda were included in this study. In Souza, Brazil,
samples were collected from individuals who were infected during a P. vivax outbreak in an otherwise
malaria-free region (39). Samples from ﬁve individuals were tested in this study. Malaria-exposed
individuals were recruited from the agricultural settlement of Rio Pardo, in the Brazilian Amazon, to
participate in a population-based open cohort study initiated in November 2008 (71). In this study, we
included samples from individuals who were positive for exposure to P. vivax (based on PvMSP1
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reactivity) but negative for P. falciparum exposure (based on PfMSP1 reactivity). Samples were also
collected from unexposed Brazilians living in Belo Horizonte and used as negative controls. In Colombia,
both symptomatic and asymptomatic men and children (including girls under 12 years of age) were
recruited between 2013 and 2016 in the municipality of Puerto Libertador in the Department of Córdoba.
Serum samples were collected in the community as part of a cross-sectional survey (asymptomatic
cohort) and from individuals presenting to the clinic with suspected malaria (25). Serum samples from
50 unexposed individuals living in Medellín, Colombia, were also collected and used as negative controls.
In Bugiri, Uganda, plasma samples were collected from individuals over 1 year of age who presented to
the clinic with suspected malaria, as part of another study (72). The samples used in this study were
collected from male children and multigravid women, who were pregnant at the time of collection.
Mice. Mice used for the Sal 1 immunizations were purchased from Harlan Animal Research Labora-
tories and housed in the University of South Florida Animal Facility. Female BALB/c mice (6 to 8 weeks
old) were used for immunizations. All procedures were approved by the Institutional Animal Care and
Use Committee. Mice used for the DBL5 immunizations were purchased from Charles River Laboratories
and housed in the University of Alberta Animal Facility in a virus antibody-free room. Female BALB/c mice
(6 to 8 weeks old) were used for immunizations. All procedures were approved by the University of
Alberta Animal Care and Use Committee, and mice were handled in accordance with the Canadian
Council on Animal Care guidelines.
Synthetic peptide design. The SD1ss peptide was synthesized (Synpeptides Co.) with the following
sequence: ASNTVMKNSNYKRKRRERDWDCNTKKDVCIPDRRYQLSMK. In this peptide, two of the cysteines
(C9 and C38) were mutated to serine to ensure that only one disulﬁde bond could form. Thirty-one
overlapping 20-mer peptides were designed to cover the entire DBL5 domain of VAR2CSA (Mimotopes).
ELISAs. For indirect ELISAs, 96-well plates (catalogue no. 439454; Thermo Fisher Scientiﬁc) were
coated with antigen in 1 phosphate-buffered saline (PBS) overnight at 4°C (antigen concentrations are
listed in Table S1 in the supplemental material). For ELISAs using peptides treated with DTT, the peptides
were incubated with DTT (10 mM) at 56°C for 10 min and then added to the plate. Wells were blocked
with 4% bovine serum albumin (BSA) (catalogue no. A7906; Sigma-Aldrich) for 1 h at 37°C followed by
incubation with the primary antibody for 1 h at room temperature (RT) (antibody dilutions are listed in
Table S1). After four washes with 1 PBST (0.01% Tween 20), a horseradish peroxidase (HRP)-conjugated
secondary antibody was added and the plate was incubated for 1 h at RT (secondary antibody dilutions
are listed in Table S1) (goat anti-rabbit HRP, catalogue no. 65-6120 [Invitrogen]; goat anti-mouse HRP,
catalogue no. 170-6516 [Bio-Rad]; goat anti-human HRP, catalogue no. ab98624 [Abcam]). The plate was
again washed four times with 1 PBST before the developing reagent (3,3=,5,5=-Tetramethylbenzidine
[TMB], catalogue no. T0440; Sigma-Aldrich) was added to each well. The reaction was stopped after
30 min at RT by addition of an equal amount of sulfuric acid (0.5 N), and the optical density (OD) of each
well was measured at 450 nm. All samples were run in duplicate, and the average OD for the antigen plus
secondary antibody alone was subtracted from the OD of all samples.
Peptide competition ELISAs were performed as described for indirect ELISAs, except that the primary
antibody was ﬁrst incubated with a test peptide (SD1ss, 0.01, 0.1, and 1.0 g/ml; all other peptides,
100 g/ml) for 30 min at RT before being added to the plate.
Antibody competition ELISAs were also performed as described for the indirect ELISA, except that a
competing antibody was added to the plate after blocking. The plate was then washed four times with
1 PBST, and the detecting antibody was added. Following another set of washes, an HRP-conjugated
secondary antibody directed against the detecting antibody was added.
Immunization scheme. For the DBPII (Sal 1 allele) immunizations, 15 female BALB/c mice (6 to
8 weeks old) were immunized as previously described (73). Mice were given three doses of recombinant
DBPII (Sal 1 allele) (25 g/mouse) emulsiﬁed in TiterMax Gold (catalogue no. T2684; Sigma) subcutane-
ously (s.c.) at days 0, 21, and 42. The ﬁnal serum samples were collected 3 weeks after the last
immunization.
For the DBL5 immunizations, a female BALB/c (6 to 8 weeks old) mouse was immunized s.c. with
recombinant DBL5 in 2% Alhydrogel (CAS no. 21645-51-2; Brenntag Biosector) at day 0 (30 g/mouse),
day 21 (10 g/mouse), and day 31 (10 g/mouse), and serum was collected on day 45.
Sequencing of Brazilian isolate. Genomic DNA was extracted from 300 l of whole blood using a
genomic DNA puriﬁcation kit (Puregene; Gentra Systems), according to the manufacturer’s protocol. The
DBPII region was ampliﬁed using the following primers: 5=-CCGTTATGAAGAACTGCAACTACA-3= and
5=-GAATGTGGCGGTGAATATCGAA-3=. The PCR product was isolated using the QIAquick PCR puriﬁcation
kit (catalogue no. 28104; Qiagen) and submitted for Sanger sequencing using the same primers used for
PCR ampliﬁcation.
Afﬁnity puriﬁcation. DBPII afﬁnity puriﬁcations were performed using N-hydroxysuccinimide (NHS)-
activated Sepharose beads (catalogue no. 17-0906-01; GE Healthcare) according to the manufacturer’s
guidelines. Beads (1.0 ml) were added to a ﬁlter column and washed with 13 ml ice-cold HCl (1 mM).
Recombinant DBPII (1.7 mg) dissolved in coupling buffer (200 mM NaHCO3, 500 mM NaCl, pH 8.3) was
added to the column and incubated overnight at 4°C. Flowthrough was collected following centrifuga-
tion for 2 min at 500 g for analysis of coupling efﬁciency. Any remaining active sites were deactivated
by incubating the column for 2 h at RT with 2 ml of deactivation buffer (500 mM ethanolamine, 500 mM
NaCl, pH 8.3). The column was then washed with 3 ml buffer 1 (100 mM Tris-HCl, 500 mM NaCl, pH 8.3),
followed by 3 ml of buffer 2 (100 mM sodium acetate, 500 mM NaCl, pH 4.0). These washes were repeated
three times before 5 ml of binding buffer (1 PBS) was ﬂowed through the column. The column was
prepared by washing with 3 ml elution buffer (100 mM glycine, pH 2.0), followed by 15 ml 1 PBS. Sera
from men and children in Colombia exposed to P. vivax and P. falciparum were pooled (5 ml), diluted 1:1
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in 1 binding buffer, clariﬁed using an 0.45-m ﬁlter, and then loaded onto the column and incubated
for 30 min at RT on a rocker. The column was washed with 9 ml of binding buffer until no protein was
detected in the ﬂowthrough (measured using a NanoDrop spectrophotometer). Bound antibodies were
then eluted using 5 ml of elution buffer into tubes containing an equal volume of neutralization buffer
(1 M Tris-HCl, pH 9.0).
SD1ss afﬁnity puriﬁcations were performed using NHS-activated HiTrap columns (catalogue no.
17-0716-01; GE Healthcare Life Sciences) according to the manufacturer’s guidelines. Columns were
acidiﬁed with HCl (1 mM) and coated with 1.0 mg of SD1ss in coupling buffer (200 mM NaHCO3, 500 mM
NaCl, pH 8.3). Unbound peptide or protein was then washed from the column using 3 column volumes
of coupling buffer. Any remaining active sites were deactivated by ﬂowing 2 ml of buffer A (500 mM
ethanolamine, 500 nM NaCl, pH 8.3) through the column, followed by 2 ml of buffer B (100 mM acetate,
500 mM NaCl, pH 4.0) and then another 2 ml of buffer A. This was repeated six times, with a 30-min
incubation in buffer A at RT after the third set of buffers was added. The column was then washed with
5 ml of 1 PBS, followed by 3 ml of elution buffer (0.1 M glycine-HCl, pH 2.0) and then another 10 ml of
1 PBS. Sera from men and children in Colombia exposed to P. vivax and P. falciparum were pooled
(5 ml), diluted 1:1 in 1 PBS, clariﬁed using an 0.45-m ﬁlter, and loaded onto the column. The sample
was continuously run over the column at a ﬂow rate of approximately 0.5 ml/min for 1 h. The column was
then washed with 1 PBS until no protein was detected in the ﬂowthrough (measured using a NanoDrop
spectrophotometer). Bound antibodies were then eluted using 5 ml of elution buffer into tubes con-
taining an equal volume of neutralization buffer (1 M Tris-HCl, pH 9.0).
Elution fractions from each afﬁnity puriﬁcation that contained protein were pooled, and the buffer
was exchanged with 1 PBS using an Amicon Ultra-4 centrifugal ﬁlter (catalogue no. UFC801024; Merck
Millipore). Total IgG was then puriﬁed, and the concentration was measured using a NanoDrop spec-
trophotometer.
Puriﬁcation of total IgG. Total IgG was puriﬁed from afﬁnity-puriﬁed antibodies, pooled plasma, or
serum samples using a HiTrap Protein G HP column (catalogue no. 17-0404-03; GE Healthcare Life
Sciences) according to the manufacturer’s instructions. Brieﬂy, the column was washed with 20 ml of 1
PBS before 1 ml of serum, plasma, or afﬁnity-puriﬁed antibodies was loaded onto the column. The
column was then incubated for 1 h at RT. The column was then washed with 1 PBS until there was no
protein detected in the ﬂowthrough (measured using a NanoDrop spectrophotometer). Bound IgG was
eluted using 3 ml of elution buffer (0.1 M glycine-HCl, pH 9.0) into tubes containing an equal volume of
neutralization buffer (1 M Tris-HCl, pH 9.0). Elution fractions containing protein were pooled, the buffer
was exchanged with 1 PBS using an Amicon Ultra-4 centrifugal ﬁlter, and the concentration was
measured using a NanoDrop spectrophotometer.
P. falciparum culture. P. falciparum CS2 parasites were maintained in culture at 3% hematocrit in
washed erythrocytes collected from O blood donors as described previously (74). Parasites were
regularly selected for adhesion to CSA (catalogue no. C9819; Sigma-Aldrich) to enrich for parasites
expressing VAR2CSA. Mature parasites were magnetically puriﬁed using the VarioMACS separator
according to the manufacturer’s instructions (LD columns, catalogue no. 130-042-901; Miltenyi Biotec).
Inhibition of binding assay (IBA). Ten spots were drawn in a semicircle around the outer edge of
the bottom of a Petri dish (catalogue no. 351029; Corning). Each spot was coated with 20 l CSA in 1
PBS (50 g/ml) overnight at 4°C in a humidiﬁed chamber. The spots were then blocked with 3% BSA in
RPMI (catalogue no. 31800-022; Gibco Life Technologies) for 1 h at 37°C in a humidiﬁed chamber. Mature
trophozoite-stage P. falciparum CS2 parasites were magnetically enriched using the VarioMACS separator
and diluted to 1.0 107 cells/ml at 20% parasitemia in 3% BSA in RPMI containing uninfected red blood
cells. The cells were then pelleted, and the supernatant was replaced with either soluble CSA as a control
(100 g/ml) or antibodies diluted in 1 PBS (DBPII afﬁnity-puriﬁed IgG, 100 g/ml; SD1ss afﬁnity-puriﬁed
IgG, 90 g/ml; total IgG from unexposed Colombians, 90 or 100 g/ml to match concentration of
afﬁnity-puriﬁed IgG). The samples were then incubated for 30 min at RT, and 20 l was added to the
CSA-coated spots. The plates were incubated for 15 min at RT. Plates were then placed on a rocker in a
position such that PBS could be added to the lower portion of the plate and not come into contact with
the spots. PBS (1; 19 ml) was added to each plate, and the rocker speed was slowly increased, while a
further 6 ml of 1 PBS was slowly added to the plate. The plates were washed for 8 min on the rocker
before the PBS was aspirated from the plates, and the remaining cells were ﬁxed by slowly adding 10 ml
of 1.5% glutaraldehyde and incubating at RT for 10 min. The cells were stained with 10 ml of 5% Giemsa
stain for 5 min and washed twice with 10 ml of deionized water. To quantify the number of parasites on
each spot, the entire spot was imaged using an Evos FL Auto microscope (Invitrogen) with a 4/0.13
phase lens objective. ImageJ was used to quantify the number of iRBCs bound to each spot. All
experiments include replicates across multiple plates.
Homology modeling. The 3D7 DBL5 homology model was created as described previously (75).
Brieﬂy, the multiple alignment was submitted to the HHpred server (76), and the best hit was selected
based on score and structure resolution (VAR2CSA DBL3X, PDB ID 3BQK). The model was then validated
by submission to the ProQ server (77), and PyMOL was used to generate ﬁgures (78).
Statistical analysis. Data were plotted using Prism software (version 8; GraphPad). Seroreactivity to
different antigens was correlated using Spearman rank correlation (Fig. 3 and 4). Comparisons of parasite
counts in IBAs were made using Student’s t test (Fig. 5C and D), and comparisons of competition ELISA
data were made using one-way analysis of variance (ANOVA) with multiple-comparison tests (Fig. 6C to
F and Fig. 7A).
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SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/mBio
.02343-19.
FIG S1, TIF ﬁle, 2.8 MB.
FIG S2, TIF ﬁle, 2.8 MB.
TABLE S1, PDF ﬁle, 0.1 MB.
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